CTOs on the Move

resTORbio

www.restorbio.com

 
resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.restorbio.com
  • 501 Boylston Street Suite 6102
    Boston, MA USA 02116
  • Phone: 617.482.2333

Executives

Name Title Contact Details

Funding

resTORbio raised $40M on 11/30/2017

Similar Companies

Lorian Home Health

Lorian Home Health is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Koronis Pharmaceuticals

Koronis Pharmaceuticals is a Redmond, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PT Development LLC.

PT Development (PTD) is a Louisville-based operational management firm that specializes in providing operational efficiencies such as accounting, customer service, marketing, compliance, and human resource services to privately held physical therapy practices.   Founded by Dr. Larry Benz in 1994, PTD’s primary goal is to help our clients achieve clinical excellence through aligning business strategies, streamlining processes, and building equity through quality customer service.

iCyt Mission Technology

iCyt Mission Technology is a Champaign, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambys

Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver disease. Founded by world-renowned experts in liver disease and regenerative medicine, Ambys is pioneering the application of novel modalities including cell and gene therapy, and gain-of-function drug therapy, to meet the urgent need for treatments that have the potential to restore liver function and prevent the progression to liver failure across multiple liver diseases that are untreatable or poorly treated today. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals with $140M in starting capital and is headquartered in South San Francisco, Calif.